PROJECT SUMMARY/ABSTRACT
While several pharmacotherapies are currently available for nicotine dependence, smoking cessation is only 7.5%
successful. Recent advances in the study of genetic contributions to nicotine dependence represent a promising avenue
for the development of novel smoking cessation therapies. Our lab has shown that variations in the gene for Neuregulin
3 (NRG3) and its cognate receptor ErbB4 are linked to smoking cessation outcomes and may be responsible, in part, for
affective nicotine withdrawal (WD) phenotypes. Therefore, the overarching goal of this fellowship-training proposal is to
systematically investigate the region-specific, functional role of the Neuregulin Signaling Pathway during nicotine use and
WD. To accomplish this, we are evaluating two central aims: 1) Determine the PFC-specific contributions of ErbB4 to
nicotine WD related behavioral phenotypes and the mechanism by which they occur, and 2) Characterize expression
patterns of NRG3-ErbB4 signaling within the prefrontal cortex and identify the molecular alterations induced during
chronic nicotine and WD. Our approach is significant because it utilizes a novel genetic mouse model of nicotine
dependence in a multidimensional approach to provide insight into the underlying mechanisms that define the NRG3
signaling pathway and its role in nicotine dependence. Research undertaken in this fellowship will be performed at the
University of Kentucky College of Pharmacy under the purview of the Graduate Program in Pharmaceutical Sciences, a
multidisciplinary program designed to prepare motivated individuals for academic, industrial, or government careers in
pharmaceutical and biomedical research. My mentor, Dr. Jill Turner, has helped develop a training plan for my graduate
career that consists of professional development and didactic training in techniques that will develop my understanding
and expertise in the field. The outlined training plan will help me to develop expertise in the field of
neuropharmacology/genetics of addiction, expand upon my experimental techniques, refine my experimental design and
data analysis skills, and continue to work on my presentation and networking skills. The training gained during my graduate
career under the guidance of Dr. Turner will provide me with a broad exposure to the neurobiology of substance use
disorders; in addition to my research work, these experiences will help me in my future goals of developing novel precision
therapeutics for nicotine dependence and other co-morbid psychiatric disorders. The combination of my dedicated
mentor that will assist in the development and progression of my training with innovative research venues to conduct and
share my research will warrant my success as a well-trained graduate student.